web analytics
16.3 C
Saturday, May 28, 2022

Successful Dividend Review Boosts Generex Biotechnology Corporation (OTCMKTS:GNBT)

Generex Biotechnology Corporation (OTCMKTS:GNBT) has seen a significant rise in recent days after the Company reported the successful completion of the FINRA review process for the dividend. After an exhaustive and long review, FINRA has determined that the original August 30 record date is too long ago to adequately track all the pay due bills from stock being bought and sold by investors, so a new record date of February 17th, 2020 has been established. This will insure everyone who has bought stock since August and retains the stock will receive the dividend not by way of a Pay Due Bill, but rather, directly from Generex. Those who sold stock after the original record date need not worry about anything as they were formally entitled to receive the dividend, but they would have had to transfer the dividend to the buyer of their shares. With the new February 17th record date being established, those who are entitled to receive the 5/2 stock dividend in Generex and the 5/2 stock dividend in NuGenerex Immuno-Oncology will receive it directly from the company.

Generex Biotechnology bills itself as an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. GNBT does have an exciting story behind it; the Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity and was making some advancements last year

GNBT also has a wholly owned subsidiary Antigen Express, Inc. focused on immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.

Antigen Express has previously published its work on the development of a vaccine for potentially pandemic viruses such as the H5N1 (avian flu) and H1N1 (swine flu) influenza strains. The advantage of the technology is that it entails entirely synthetic production methods, which are rapid, cost effective, and flexible. The vaccine is produced using a small fragment derived from a target protein modified to ensure activation of CD4+ T helper cells. This cell type is critical in the generation of an effective immune response to a novel agent.

To Find out the inside Scoop on GNBT Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Also on February 7 GNBT said In addition, the pay date is now February 24th and ex-date is February 25th. If a shareholder sells the stock after the record date the pay due bill process will be in full effect and the shareholder will be required to transfer the dividend stock to the buyer. The ex-date rule in this situation is found in FINRA Rules Section 11140 (b)(2), which reads as follows: “(2) In respect to cash dividends or distributions, stock dividends and/or splits, and the distribution of warrants, which are 25% or greater of the value of the subject security, the ex-dividend date shall be the first business day following the payable date.” As always, speak to your financial advisor for more information.

“After a long and challenging process, we are finally able to deliver the promised stock dividends to our loyal shareholders”, said Joe Moscato, President & CEO of Generex. “We have worked in collaboration with FINRA to agree on this revised plan with a new and definitive timeline. We are very happy to have definitive dates for this dividend that shareholders have been prudently waiting for. Paying the dividend is fantastic for all stakeholders in Generex, as it will enable us to file the second part of our S1 registration statement with financial terms that of the offering, which could only be done after paying the dividend. Also, with this approval from FINRA, we are now able to execute on our strategic and operational plans, including the spin-out of NuGenerex Immuno-Oncology onto the Nasdaq, so Generex can realize the substantial value of the Ii-Key immunotherapy platform. We will advance the clinical trial program for Regentys ECMH for the treatment of ulcerative colitis and Crohn’s Disease. We will expand the sales and marketing efforts for Excellagen wound conforming gel matrix as approvals continue throughout the VA system and the Indian Health Service, and we will implement the launch of our new product offering from Olaregen, Olarex, an umbilical cord tissue product that is widely used in surgery and regenerative medicine applications. At Pantheon, we plan to increase production and expand sales of foot and ankle kits, and we will expedite our plans for MediSource to introduce new orthopedic implants and biologic products.”

Mr. Moscato also said the Company has exciting plans to launch our new MSO model that offers orthopedic surgeons and podiatrists in the MSO network an opportunity to order wound care and orthopedic products directly from the NuGenerex family of companies at discounted prices through the group purchasing system of the MSO. We will also offer the recently optimized DME-IQ software and service for orthopedic medicine groups to manage their durable medical equipment inventory and billing, and we have plans to integrate additional software and DME services going forward. Lastly, we can execute our plans to start our diabetes focused MSO, NuGenerex Health in partnership with three major physician practices in Arizona.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $33 million market valuation GNBT has $52 million in assets including $38 million in goodwill and over $24 million in current liabilities. The Company also boasts strong sales reporting $721k in revenues for the 3 months ended October 31, 2019. GNBT just reported the successful completion of the FINRA review process for the dividend. After an exhaustive and long review, FINRA has determined that the original August 30 record date is too long ago to adequately track all the pay due bills from stock being bought and sold by investors, so a new record date of February 17th, 2020 has been established. We will be updating GNBT as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with GNBT.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in GNBT either long or short and we have not been compensated for this article.

More articles


Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.